Dergiler / Turkish Neurosurgery / 2016 / Cilt: 26 - Sayı: 5

The Effect of Matrix Metalloproteinase-3 on the Prognosis and Biological Behaviour of Meningiomas

Sayfa
678–683
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

MMP-3 may be used as a proliferation marker for biological behaviour, recurrence rate and prognosis of meningiomas.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:AIM: To analyse the effect of MMP-3 (Matrix Metalloproteinase Enzyme-3)-one of the extracellular matrix proteins- on the prognosis and biological behaviour of meningiomas.
📊
Temel Bulgular & Veri:MATERIAL and METhODS: 79 cases of meningioma that were operated in our clinic between 2005 and 2010 were retrospectively analysed.
💡
Sonuç & Katkı:MMP-3 may be used as a proliferation marker for biological behaviour, recurrence rate and prognosis of meningiomas.
🔬Tür:Araştırma Makalesi
📍Kapsam:2005 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

AIM: To analyse the effect of MMP-3 (Matrix Metalloproteinase Enzyme-3)-one of the extracellular matrix proteins- on the prognosis and biological behaviour of meningiomas. MATERIAL and METhODS: 79 cases of meningioma that were operated in our clinic between 2005 and 2010 were retrospectively analysed. Age, sex, preoperative peritumoral edema, histological subtype, grade, Ki-67 expression, MMP-3 staining pattern and recurrence rate were analysed. Pathological preparations were graded according to the WHO (World Health Organisation) 2007 grading system. RESULTS: Of the MMP-III positive cases; 24 cases (60%) were grade I, 16 cases were grade II. The MMP-3 staining pattern was significantly positive (80%) in grade II meningioma. 14 of the MMP-3 positive cases were atypical meningiomas. Of the 20 cases with high Ki-67 proliferation index (PI), 12 cases (60%) were MMP-3 positive and 8 cases (40%) were MMP-3 negative. Rates of recurrence and preoperative peritumoral edema were high in cases with MMP-3 positivity. CONCLUSION: In this study it was determined that MMP-3 positivity has a strong relationship with meningiomas having an aggressive character. MMP-3 may be used as a proliferation marker for biological behaviour, recurrence rate and prognosis of meningiomas.

🔖

Bu Makaleye Atıf Yap

KARAARSLAN, N., GÜRBÜZ, M. S., CALISKAN, T., AYAN, E., AKER, F. V., BERKMAN, M. Z. (2016). The Effect of Matrix Metalloproteinase-3 on the Prognosis and Biological Behaviour of Meningiomas. Turkish Neurosurgery, Cilt: 26 - Sayı: 5, 678–683. https://ajindex.com/articles/405407

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Akyildiz EU, Oz B, Comunoglu N, Aki H: The relationship between histomorphological characteristics and Ki-67 proliferation index in meningiomas. Bratisl Lek Listy 111(9): 505-509, 2010 2. Asha D, Wan-Loo T, Duncan RS: Expression of extracellular matrix markers in benign meningiomas. Neuropathol 23: 275- 281, 2003 3. Barresi V, Vitarelli E, Tuccari G, Baressi G: MMP-9 expression in meningiomas: A prognostic marker for recurrence risk? J Neurooncol 102: 189-196, 2011 4. Bomsan FT, Stamenkovic I: Functional structure and composition of extracellular matrix. J Pathol 200: 423-428, 2003 5. Cushing H, Eisenhardt L: Meningiomas: Their classification, regional behavior, life history, and result. Springfield, IL: Hafner Publishing Co, 1938: 49-224 6. Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002 7. Haro H, Crawford HC, Fingleton B: Matrix metalloproteinase-3- dependent generation of a macrophage chemoattractant in a model of herniated disc resorption. J Clin Invest 105: 133- 141, 2000 8. Ho DM, Hsu CY, Ting LT, Chiang H: Histopathology and MIB-1 labeling index predicted recurrence of meningiomas. Cancer 94(5): 1338-1347, 2002 9. Kayaselçuk F, Zorludemir S, Bal N, Erdogan B, Erdogan S, Erman T: The expression survivin and Ki-67 in meningiomas: Correlation with grade and clinical outcome. J Neurooncol 67: 209-214, 2004 10. Kayasu H, Kubo O, Tanaka M, Amano K, Kato K, Hori T: Clinical and radiological features related to growth potential of meningioma. Neurosurg Rev 29: 293-297, 2006 11. Lemaître V, D'Armiento J: Matrix Metalloproteinases in Development and Disease. Birth Defects Res C Embryo Today 78:1-10, 2006 12. Lijnen HR, Arza B, Van Hoef B, Collen D, Declerck PJ: Inactivation of Plasminogen Activator Inhibitor-1 by Specific Proteolysis with Stromelysin-1 (MMP-3). J Biol Chem 278: 37645-37650, 2000 13. Lund LR, Romer J, Thomasset N: Two distinct phases of apoptosis in mammary gland involution: Proteinasesindependent and dependent pathways. Development 122: 181-193, 1996 14. Mannello F, Luchetti F, Falcieri E, Papa S: Multiple roles of matrix metalloproteinases during apoptosis. Apoptosis 10: 19-24, 2005 15. Marcy Al, Eiberger LL, Harrison R: Human fibroblast stromelysin catalytic domain: Expression, purification, and characterization of a C-terminally truncated from. Biochemistry 30(26): 6476-6483, 1991 16. Matrisian LM: Metalloproteinases and their inhibitors in matrix remodeling. Tre